Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm

Publikation: Bidrag til tidsskriftKommentar/debatForskningfagfællebedømt

Standard

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm. / Pedersen, Kasper Mønsted; Çolak, Yunus; Hasselbalch, Hans Carl; Bojesen, Stig Egil; Nordestgaard, Børge Grønne.

I: EClinicalMedicine, Bind 22, 100337, 2020.

Publikation: Bidrag til tidsskriftKommentar/debatForskningfagfællebedømt

Harvard

Pedersen, KM, Çolak, Y, Hasselbalch, HC, Bojesen, SE & Nordestgaard, BG 2020, 'Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm', EClinicalMedicine, bind 22, 100337. https://doi.org/10.1016/j.eclinm.2020.100337

APA

Pedersen, K. M., Çolak, Y., Hasselbalch, H. C., Bojesen, S. E., & Nordestgaard, B. G. (2020). Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm. EClinicalMedicine, 22, [100337]. https://doi.org/10.1016/j.eclinm.2020.100337

Vancouver

Pedersen KM, Çolak Y, Hasselbalch HC, Bojesen SE, Nordestgaard BG. Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm. EClinicalMedicine. 2020;22. 100337. https://doi.org/10.1016/j.eclinm.2020.100337

Author

Pedersen, Kasper Mønsted ; Çolak, Yunus ; Hasselbalch, Hans Carl ; Bojesen, Stig Egil ; Nordestgaard, Børge Grønne. / Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm. I: EClinicalMedicine. 2020 ; Bind 22.

Bibtex

@article{b225273c60b74489bef43fb9838ce8d8,
title = "Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm",
author = "Pedersen, {Kasper M{\o}nsted} and Yunus {\c C}olak and Hasselbalch, {Hans Carl} and Bojesen, {Stig Egil} and Nordestgaard, {B{\o}rge Gr{\o}nne}",
year = "2020",
doi = "10.1016/j.eclinm.2020.100337",
language = "English",
volume = "22",
journal = "EClinicalMedicine",
issn = "2589-5370",
publisher = "The Lancet Publishing Group",

}

RIS

TY - JOUR

T1 - Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm

AU - Pedersen, Kasper Mønsted

AU - Çolak, Yunus

AU - Hasselbalch, Hans Carl

AU - Bojesen, Stig Egil

AU - Nordestgaard, Børge Grønne

PY - 2020

Y1 - 2020

U2 - 10.1016/j.eclinm.2020.100337

DO - 10.1016/j.eclinm.2020.100337

M3 - Comment/debate

C2 - 32395710

AN - SCOPUS:85084090260

VL - 22

JO - EClinicalMedicine

JF - EClinicalMedicine

SN - 2589-5370

M1 - 100337

ER -

ID: 250166452